Big Pharma Split Corp Class A sees modest gains this week amidst distribution announcements.
Big Pharma Split Corp Class A (PRM.TO) experienced a slight uptick in its stock price this week, closing at C$14.08, marking a 1.28% increase on Wednesday and a 1.93% rise over the week. The stock has been buoyed by recent announcements regarding cash distributions for its Class A shares.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Big Pharma Split Corp Class A
PRM.TO
PRM.TO
Big Pharma Split Corp Class A
WealthAwesomeMarket cap
$18.36M
52W high
$15.04
52W low
$10.03
1W change
+1.93%
Beta
0.73
Analyst Price Targets
Based on analyst covering PRM
Wall Street analysts forecast PRM stock price to fall 86.0% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.00
-86.0% Upside
Current Price
C$14.27
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PRM's historical volatility
30-Day Vol
26.4%
Annualized
90-Day Vol
29.6%
Annualized
Trend (90d)
+12.2%
Annualized drift
90d Mean
C$14.91
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$14.48 | C$13.22 โ C$15.86 |
| 60 trading days | C$14.69 | C$12.92 โ C$16.71 |
| 90 trading days | C$14.91 | C$12.73 โ C$17.45 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors in Big Pharma Split Corp Class A may find the recent distribution announcements a positive signal, though the stock remains below its 52-week high. With a profit margin of 86.1% and a relatively low beta of 0.73, the stock may appeal to those seeking stability in the financial sector.
Big Pharma Split Corp Class A's Profit Margin Stands at 86.1%
With a profit margin of 86.1%, Big Pharma Split Corp Class A demonstrates strong operational efficiency, though the EPS remains negative at -1.95.
Bull case
The companyโs high profit margin and a strong return on equity (ROE) of 27.6% indicate solid financial health. This could attract income-focused investors looking for reliable options in the market.
Bear case
However, analysts have a bearish outlook, with an average target of C$2.00, suggesting there could be significant downside potential from the current price level.
Recent Price Action
Big Pharma Split Corp Class A closed at C$14.08 on Wednesday, reflecting a 1.28% gain for the day and a 1.93% increase over the past week. The stock has shown a positive trend recently, with a 1-month increase of 3.48% and a year-to-date rise of 5.55%.
Catalysts and Company News
This week, Big Pharma Split Corp Class A was in the spotlight due to announcements from Harvest Portfolios Group Inc. regarding cash distributions. The company declared a monthly cash distribution of $0.1031 per Class A share for both February and March 2026, which is payable in the following months. These announcements may provide some reassurance to investors looking for income generation.
Technical Picture
From a technical perspective, Big Pharma Split Corp Class A is trading above its 50-day moving average (C$13.84) by approximately 1.8% and is also above its 200-day moving average (C$13.77) by about 2.3%. The stock's 52-week range has been between C$10.03 and C$15.04, indicating it is currently trading at 81% of its range. With a beta of 0.73, the stock has shown lower volatility compared to the market.
Insider Activity
No recent insider activity has been reported for Big Pharma Split Corp Class A, which may suggest stability in management and ownership.
Price Action Summary
Big Pharma Split Corp Class A closed at C$14.08, reflecting a 1D increase of 1.28%. Investors may want to watch for further developments surrounding the company's distributions and market performance.
Advertisement
